Table 5.
Responses
| Best Response | Cohort 1 (n = 27) |
All Patients (N = 71) |
||||
|---|---|---|---|---|---|---|
| Response |
Response Duration (months) | Response |
Response Duration (months) | |||
| No. | % | No. | % | |||
| CR | 3 | 11 | 6, 14*, 63† | 4 | 7 | 6, 14*, 26‡, 63† |
| PR | 8 | 30 | 2§, 2, 5, 10, 14, 20§, 32, 76‡ | 20 | 26 | 1, 1, 2, 2, 2, 2§, 3, 4‡, 5, 5, 6‖, 7§, 10, 11‡, 14, 14, 15, 20§, 32, 76‡ |
| SD | 10 | 37 | 3, 3, 4, 4, 4, 6, 6, 7, 7, 8 | 26 | 38 | 3, 3, 3, 3, 3, 4, 4, 4, 4, 4, 4, 4, 4, 4‖, 5, 6, 6, 6, 6, 6, 7, 7, 8, 8, 10, 11 |
| PD | 3 | 11 | 15 | 17 | ||
| NE | 3 | 11 | 6 | 12 | ||
Abbreviations: CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; NE, not evaluable.
After 14 months in CR, this patient developed several small plaques but did not require additional therapy for over 43 months.
Patient completed therapy 58 months prior to cut off date for this report.
Patients with continued responses to therapy at time of this report.
Patient self-withdrew from study.
Death on study.